Published in Arch Intern Med on November 28, 2011
Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights. Circ Cardiovasc Qual Outcomes (2012) 0.97
Timeliness of interfacility transfer for ED patients with ST-elevation myocardial infarction. Am J Emerg Med (2015) 0.85
Decreasing door-to-balloon times via a streamlined referral protocol for patients requiring transport. Am J Emerg Med (2013) 0.82
Recent Advances in the Treatment of ST-Segment Elevation Myocardial Infarction. Scientifica (Cairo) (2012) 0.77
Role of Health Insurance Status in Interfacility Transfers of Patients With ST-Elevation Myocardial Infarction. Am J Cardiol (2016) 0.75
System dynamics modeling in the evaluation of delays of care in ST-segment elevation myocardial infarction patients within a tiered health system. PLoS One (2014) 0.75
Association of Emergency Department Length of Stay and Crowding for Patients with ST-Elevation Myocardial Infarction. West J Emerg Med (2015) 0.75
Association Between Hospital Practices and Door-in-door-out Time in ST-segment Elevation Myocardial Infarction. Crit Pathw Cardiol (2016) 0.75
Performance of Emergency Department Screening Criteria for an Early ECG to Identify ST-Segment Elevation Myocardial Infarction. J Am Heart Assoc (2017) 0.75
Unmet goals in the treatment of Acute Myocardial Infarction: Review. F1000Res (2017) 0.75
A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med (2003) 9.00
Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med (2006) 8.18
Time to treatment in primary percutaneous coronary intervention. N Engl J Med (2007) 3.95
Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation (2005) 3.78
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. JAMA (2004) 3.45
A campaign to improve the timeliness of primary percutaneous coronary intervention: Door-to-Balloon: An Alliance for Quality. JACC Cardiovasc Interv (2008) 2.69
System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA (2010) 2.53
Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation (2007) 2.47
Improvements in door-to-balloon time in the United States, 2005 to 2010. Circulation (2011) 2.13
Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA (2007) 2.10
Time is muscle: translation into practice. J Am Coll Cardiol (2008) 1.60
National efforts to improve door-to-balloon time results from the Door-to-Balloon Alliance. J Am Coll Cardiol (2009) 1.57
Care processes associated with quicker door-in-door-out times for patients with ST-elevation-myocardial infarction requiring transfer: results from a statewide regionalization program. Circ Cardiovasc Qual Outcomes (2011) 1.56
Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. JAMA (2011) 1.48
Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. Circulation (2006) 1.39
Comparative effectiveness of ST-segment-elevation myocardial infarction regionalization strategies. Circ Cardiovasc Qual Outcomes (2010) 1.28
Impact of a statewide ST-segment-elevation myocardial infarction regionalization program on treatment times for women, minorities, and the elderly. Circ Cardiovasc Qual Outcomes (2010) 1.27
Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. J Am Coll Cardiol (2008) 1.19
Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention. Am Heart J (2005) 1.03
Using prehospital electrocardiograms to improve door-to-balloon time for transferred patients with ST-elevation myocardial infarction: a case of extreme performance. Circ Cardiovasc Qual Outcomes (2010) 0.89
Moving toward improved care for the patient with ST-elevation myocardial infarction: a mandate for systems of care. Circ Cardiovasc Qual Outcomes (2010) 0.85
Trends in race-based differences in door-to-balloon times. Arch Intern Med (2010) 0.84
Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA (2004) 14.05
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA (2008) 12.36
Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med (2009) 11.51
Understanding the treatment preferences of seriously ill patients. N Engl J Med (2002) 10.84
Telemonitoring in patients with heart failure. N Engl J Med (2010) 10.82
Public reporting and pay for performance in hospital quality improvement. N Engl J Med (2007) 10.55
Delayed time to defibrillation after in-hospital cardiac arrest. N Engl J Med (2008) 8.36
Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med (2006) 8.18
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA (2007) 7.12
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med (2009) 6.89
Duration of resuscitation efforts and survival after in-hospital cardiac arrest: an observational study. Lancet (2012) 6.60
Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ (2012) 6.39
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35
An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes (2008) 6.00
The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med (2005) 5.86
Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med (2002) 5.74
Does this woman have an acute uncomplicated urinary tract infection? JAMA (2002) 5.74
Trends in survival after in-hospital cardiac arrest. N Engl J Med (2012) 5.67
Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes (2009) 5.66
Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med (2005) 5.49
Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA (2013) 5.27
National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA (2011) 5.16
Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA (2003) 5.09
Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA (2006) 5.06
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99
Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA (2002) 4.92
Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med (2002) 4.80
National trends in use of computed tomography in the emergency department. Ann Emerg Med (2011) 4.72
The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med (2008) 4.70
Regulatory review of novel therapeutics--comparison of three regulatory agencies. N Engl J Med (2012) 4.50
Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med (2002) 4.45
Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44
Consequences of inadequate sign-out for patient care. Arch Intern Med (2008) 4.39
Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA (2003) 4.38
Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA (2010) 4.36
Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation (2006) 4.35
Appropriateness of percutaneous coronary intervention. JAMA (2011) 4.33
Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA (2009) 4.29
Qualitative and mixed methods provide unique contributions to outcomes research. Circulation (2009) 4.28
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA (2009) 4.24
Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol (2004) 4.14
Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2006) 4.11
Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med (2012) 4.02
Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail (2009) 3.95
Time to treatment in primary percutaneous coronary intervention. N Engl J Med (2007) 3.95
Long-term outcomes in elderly survivors of in-hospital cardiac arrest. N Engl J Med (2013) 3.85
Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol (2006) 3.85
When choosing statin therapy: the case for generics. JAMA Intern Med (2013) 3.80
Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation (2005) 3.78
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
Association between stroke center hospitalization for acute ischemic stroke and mortality. JAMA (2011) 3.68
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis. J Cardiovasc Electrophysiol (2010) 3.56
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45